Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus apatinib with or without chemotherapy for resectable stage II-IIIA NSCLC
ChiCTR1900023540Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Safety and Major pathologic response. Started Jan 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900023540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023540.